IPP Bureau
MTPA announces long-term findings from post-marketing safety study of Radicava
By IPP Bureau - June 30, 2022
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Pfizer and BioNTech inks new agreement with US Government to provide additional doses of COVID-19 vaccine
By IPP Bureau - June 30, 2022
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
By IPP Bureau - June 30, 2022
The settlement and dismissal resolves all claims between the parties
Glenmark Pharmaceuticals expand its OTC portfolio
By IPP Bureau - June 29, 2022
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3
By IPP Bureau - June 29, 2022
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions
By IPP Bureau - June 29, 2022
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
DTx Pharma appoints Peter Condon as Chief Business Officer
By IPP Bureau - June 29, 2022
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Govt calls upon states to step up vigil against Covid
By IPP Bureau - June 29, 2022
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
Apollo Education UK launches the Apollo International Clinical Fellowship Programme
By IPP Bureau - June 29, 2022
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
Wacker to build biotechnology center in Munich
By IPP Bureau - June 28, 2022
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
Balaxi Pharmaceuticals' Hyderabad factory to be operational by March 2024
By IPP Bureau - June 28, 2022
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
HIL to commercialise VCRC Bti bio-larvicide technology for mosquito vector control programs
By IPP Bureau - June 28, 2022
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
R&D key for the growth of nation: Dr. Mandaviya
By IPP Bureau - June 28, 2022
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
Medidata launches new clinical operations technologies to address clinical trial oversight issues
By IPP Bureau - June 28, 2022
Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies
Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
By IPP Bureau - June 28, 2022
Strengthens investment in channels of the future to expand patient reach
